Postpartum Hemorrhage Emerges as a Key Outcome of Maternal SARS-CoV-2 Omicron Variant Infection Surge Across Pregnancy Trimesters DOI Creative Commons
Xu Zhou, E Li, Jia Liu

et al.

Journal of Infection and Public Health, Journal Year: 2025, Volume and Issue: 18(6), P. 102733 - 102733

Published: March 6, 2025

Despite evidence showing changes in disease severity with the virus's evolution and vaccination efforts, link between maternal, perinatal, neonatal outcomes SARS-CoV-2 infections during different pregnancy trimesters remains unclear, especially BA.5 BF.7 Omicron subvariant surge China December 2022. This study investigates correlation infection across various trimesters. prospective cohort was conducted at two hospitals southwest China, examining clinical records status of 2158 pregnant women registered January 1, 2022, September 30, 2023. Initially shielded from COVID-19, population later experienced a significant surge. A comparative analysis evaluated infected uninfected subjects. Primary included complications premature births, while secondary encompassed cesarean sections, delivery complications, outcomes. Pregnant had higher incidence placenta increta/percreta postpartum hemorrhage compared to women. First trimester were associated lower intrahepatic cholestasis [aOR = 0.29, 95 % CI 0.13-0.63] but preterm birth 2.16, 1.25-3.71]. Third increased risk 2.74, 1.21-6.18]. is linked hemorrhage. are pregnancy, third

Language: Английский

Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial DOI
Carolyn T. Bramante, John B. Buse, David Liebovitz

et al.

The Lancet Infectious Diseases, Journal Year: 2023, Volume and Issue: 23(10), P. 1119 - 1129

Published: June 8, 2023

Language: Английский

Citations

154
Etiologically Based Functional Taxonomy of the Preterm Birth Syndrome DOI
José Villar, Paolo Ivo Cavoretto, Fernando C. Barros

et al.

Clinics in Perinatology, Journal Year: 2024, Volume and Issue: 51(2), P. 475 - 495

Published: April 4, 2024

Language: Английский

Citations

26
Clinical course and management of COVID-19 in the era of widespread population immunity DOI
Eric A. Meyerowitz, Jake Scott, Aaron Richterman

et al.

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 22(2), P. 75 - 88

Published: Dec. 19, 2023

Language: Английский

Citations

35
Effect of COVID-19 vaccination and booster on maternal–fetal outcomes: a retrospective cohort study DOI Creative Commons
Samantha N. Piekos, Yeon Mi Hwang, Ryan Roper

et al.

The Lancet Digital Health, Journal Year: 2023, Volume and Issue: 5(9), P. e594 - e606

Published: Aug. 1, 2023

COVID-19 in pregnant people increases the risk for poor maternal-fetal outcomes. However, vaccination hesitancy remains due to concerns over vaccine's potential effects on Here we examine impact of and boosters maternal SARS-CoV-2 infections birth

Language: Английский

Citations

33
Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study DOI Creative Commons
Fernando C. Barros, Robert B. Gunier,

Albertina Rego

et al.

American Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 231(4), P. 460.e1 - 460.e17

Published: Feb. 16, 2024

Language: Английский

Citations

12
Facilitators and barriers to vaccination uptake in pregnancy: A qualitative systematic review DOI Creative Commons
Mohammad S Razai, Rania Mansour, Pahalavi Ravindran

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(4), P. e0298407 - e0298407

Published: April 19, 2024

Introduction Vaccination during pregnancy protects both the mother and foetus from vaccine-preventable diseases. However, uptake of recommended vaccines (influenza, pertussis, COVID-19) by pregnant women remains low in Europe USA. Understanding reasons for this is crucial to inform strategies increase vaccination rates women. This qualitative systematic review aimed identify barriers facilitators against influenza, pertussis/whooping cough COVID-19 possible rates. Methods We conducted a comprehensive search electronic databases, including Medline, PsycINFO, CINAHL, Web Science, WHO database, Embase grey literature studies that explored vaccine among (PROSPERO CRD42023399488). The was limited published between 2012 2022 high-income countries with established programmes pregnancy. Studies were thematically analysed underwent quality assessment using Joanna Briggs Institute validated critical appraisal tool research. Results Out 2681 articles screened, 28 (n = 1573 participants) eligible inclusion. Five overarching themes emerged relating personal, provider systemic factors. Barriers included concerns about safety efficacy, lack knowledge vaccines’ benefits necessity, fear adverse effects on or perception disease severity. Facilitators recommendations trusted healthcare providers, easy access vaccination, clear communication positive social influences family friends. Strategies increasing strong proactive professionals, provision routine antenatal care, consistent addressing women’s concerns. Conclusion highlights need interventions address identified Recommendation can play significant role promoting uptake, as risk/benefit convenient vaccination. Addressing providing accurate information also important.

Language: Английский

Citations

11
COVID-19 Vaccination in the First Trimester and Major Structural Birth Defects Among Live Births DOI
Elyse O. Kharbanda, Malini B. DeSilva,

Heather S. Lipkind

et al.

JAMA Pediatrics, Journal Year: 2024, Volume and Issue: 178(8), P. 823 - 823

Published: Aug. 1, 2024

Importance COVID-19 vaccination is recommended throughout pregnancy to prevent complications and adverse birth outcomes associated with disease. To date, data on defects after first-trimester are limited. Objective evaluate the risks for selected major structural among live-born infants receipt of a messenger RNA (mRNA) vaccine. Design, Setting, Participants This was retrospective cohort study singleton pregnancies estimated last menstrual period (LMP) between September 13, 2020, April 3, 2021, ending in live from March 5, January 25, 2022. Included were 8 health systems California, Oregon, Washington, Colorado, Minnesota, Wisconsin Vaccine Safety Datalink. Exposures Receipt 1 or 2 mRNA vaccine doses first trimester, as part primary series. Main Outcomes Measures Selected infants, identified electronic using validated algorithms, neural tube confirmed via medical record review. Results Among 42 156 eligible (mean [SD] maternal age, 30.9 [5.0] years) 7632 (18.1%) received an trimester. Of 34 524 without vaccination, 2045 (5.9%) vaccinated before pregnancy, 13 494 (39.1%) during second third 18 985 (55.0%) unvaccinated pregnancy. Compared pregnant people those trimester older 32.3 [4.5] years vs 30.6 [5.1] differed by LMP date. After applying stabilized inverse probability weighting, differences baseline characteristics persons negligible (standardized mean difference <0.20). occurred 113 (1.48%) 488 (1.41%) exposure; adjusted prevalence ratio 1.02 (95% CI, 0.78-1.33). In secondary analyses, defect grouped organ system, no significant identified. Conclusions Relevance this multisite study, exposure not increased risk defects.

Language: Английский

Citations

11
Preeclamptic Placental CD19+ B Cells Are Causal to Hypertension During Pregnancy DOI
Owen Herrock, Nathan Campbell, Evangeline Deer

et al.

Hypertension, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

BACKGROUND: Patients with preeclampsia exhibit hypertension and chronic inflammation characterized by CD (cluster determinant) 4+T cells, B cells secreting AT1-AA (agonistic autoantibody against the angiotensin II type 1 receptor), inflammatory cytokines, complement activation. Importantly, a history of COVID-19 during pregnancy is associated an increased incidence preeclampsia-like phenotype partly mediated CD4+T cells. We recently showed pregnant patients or without produce AT1-AA, indicating importance lymphocytes in progression possibly COVID-19. Therefore, we hypothesize that from induce through AT1-AA. METHODS: Placental were isolated normal pregnant, preeclampsia, normotensive history, at delivery. Then, 3×10 5 transferred intraperitoneally into athymic rats gestational day 12. On 18, carotid catheters inserted. 19, mean arterial pressure was measured, tissues collected. RESULTS: Preeclampsia B-cell recipients had significantly pressure, activation compared recipients. Recipients markers but not to level significance as Inhibition attenuated occurred response history. CONCLUSIONS: This study demonstrates important role contributing secretion

Language: Английский

Citations

1
Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm DOI Creative Commons
Alisa Kachikis, Mindy Pike, Linda O. Eckert

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(1), P. e2352387 - e2352387

Published: Jan. 19, 2024

Importance COVID-19 vaccine–derived antibodies in pregnant people may protect infants from severe infection the first 6 months of life via transplacental antibody transfer. Few data exist on maternally derived SARS-CoV-2 preterm compared with full-term association vaccination timing. Objective To compare anti-Spike (anti-S) levels and context vaccine dose timing before delivery. Design, Setting, Participants This prospective cohort study enrolled individuals collected paired maternal cord blood samples at delivery University Washington between February 1, 2021, January 31, 2023. who had received least 2 doses a messenger RNA did not have history prior or detectable anti–SARS-CoV-2 nucleocapsid were included. Exposures Timing last gestational age Main Outcomes Measures Paired tested for anti-S antibody, linear regression was used to evaluate associations levels. Covariates included dose, number doses, insurance status, immunosuppressing medications. Results A total 220 participants (median [IQR] age, 34 [32-37] years; 212 [96.4%] female) 36 184 deliveries studied. Before delivery, 121 persons 99 3 more doses. The geometric mean concentration 674 (95% CI, 577-787) after 8159 6636-10 032) ( P < .001). 1000 874-1144) 9992 8381-11 914) After adjustment no found (β = 0.44; 95% −0.06 0.94). Conclusions Relevance In this deliveries, receipt resulted 10-fold higher Maternal appeared important than determining considerations pregnancy should include risk

Language: Английский

Citations

7
Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis DOI Creative Commons
Silvia Fernández-García, Laura del Campo-Albendea,

Dharshini Sambamoorthi

et al.

BMJ Global Health, Journal Year: 2024, Volume and Issue: 9(4), P. e014247 - e014247

Published: April 1, 2024

Objective To assess the effects of COVID-19 vaccines in women before or during pregnancy on SARS-CoV-2 infection-related, pregnancy, offspring and reactogenicity outcomes. Design Systematic review meta-analysis. Data sources Major databases between December 2019 January 2023. Study selection Nine pairs reviewers contributed to study selection. We included test-negative designs, comparative cohorts randomised trials infection-related Non-comparative cohort studies reporting outcomes were also included. Quality assessment, data extraction analysis Two independently assessed quality extracted data. undertook random-effects meta-analysis reported findings as HRs, risk ratios (RRs), ORs rates with 95% CIs. Results Sixty-seven (1 813 947 women) Overall, design studies, pregnant fully vaccinated any vaccine had 61% reduced odds infection (OR 0.39, CI 0.21 0.75; 4 23 927 women; I 2 =87.2%) 94% hospital admission 0.06, 0.01 0.71; 868 =92%). In adjusted hypertensive disorders was by 12% (RR 0.88, 0.82 0.92; studies; 115 085 women), while caesarean section 9% 0.91, 0.85 0.98; 6 30 192 women). observed an 8% reduction neonatal intensive care unit 0.92, 0.87 0.97; 54 569 babies born versus not women. general, vaccination associated increased adverse perinatal Pain at injection site most common side effect (77%, 52% 94%; 11 27 195 Conclusion are effective preventing related complications PROSPERO registration number CRD42020178076.

Language: Английский

Citations

7